When prescribing systemic antibiotics, bacterial resistance is an important consideration.1
- The development of Propionibacterium acnes resistance can affect a patient’s clinical response to treatment2
Awareness of antibiotic resistance is high among patients and caregivers.3
- In a large survey of over 1000 patients and caregivers, the majority (over 80%) were familiar with the principles of antibiotic resistance3
as broad-spectrum antibiotics for multiple indications.4
There is limited clinical evidence supporting efficacy in treating truncal acne for tetracycline-class oral antibiotics.
- About 50% of patients with facial acne present with concomitant truncal acne9
- Acne clinical guideline. American Academy of Dermatology. Accessed June 12, 2020. https://www.aad.org/member/clinical-quality/guidelines/acne.
- Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8(1):41‐45.
- Del Rosso JQ, Rosen T, Palceski D, Rueda MJ. Patient awareness of antimicrobial resistance and antibiotic use in acne vulgaris. J Clin Aesthet Dermatol. 2019;12(6):30-41.
- Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14(14):1235-1242.
- Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610‐2616.
- Lee TW, Russell L, Deng M, Gibson PR. Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad. Intern Med J. 2013;43(8):919‐926.
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33.
- SOLODYN [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America, LLC. 2017.
- Bikowski J. A review of the safety and efficacy of benzoyl peroxide (5.3%) emollient foam in the management of truncal acne vulgaris. J Clin Aesthet Dermatol. 2010;3(11):26‐29.